Valion Bio Inc. (NASDAQ:VBIO) announced that Nasdaq Listing Qualifications Staff has formally confirmed the company’s compliance with Listing Rule 5550(a)(2), which mandates a minimum closing bid price of $1.00 per share. The confirmation follows a period during which Valion’s shares consistently closed above the threshold, prompting Nasdaq to close the compliance review.
The company’s shares closed at $2.38 on Sep 21, a gain of 12.26% from the prior session, and were trading at $2.42 in pre‑market activity, up 1.68% at 05:42 GMT. Valion’s President, COO and CFO Lisa Wolf said the compliance milestone is an important step as the firm pursues its growth strategy.
Valion Bio, based in San Antonio, develops biologics that target innate immune pathways. Its lead candidate, Entolimod, is being pursued as a medical countermeasure for acute radiation syndrome and has received Fast Track and Orphan Drug designations from the Food and Drug Administration. The company’s next‑generation TLR5 agonist, Entolasta, is intended for oncology supportive‑care applications. Valion’s wholly owned subsidiary, Velocity Bioworks, provides contract development and manufacturing services for the pipeline.
The Nasdaq notice indicates that the company satisfied the required period of maintaining a closing bid price of at least $1.00, allowing the Listing Qualifications Staff to close the matter without further action.
